NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW

NeuroSense Therapeutics Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026

$2.67−0.40 (-13.19%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

NeuroSense Therapeutics Ltd. cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Stock-Based Compensation	2.14	0.56	1.54	1.73	1.22	2.06	0.61
Other Non-Cash Items	0.05	-0.32	-0.47	-0.04	0.02	–	–
Change in Accounts Receivable	0.42	-0.75	0.02	–	–	–	–
Change in Accounts Payable	-0.36	-0.30	0.96	0.46	-0.02	0.03	0.02
Operating Cash Flow	-7.67	-10	-8.35	-7.62	-1.54	-0.70	-0.58
Capital Expenditures	-0.01	0.00	-0.03	-0.07	-0.02	-0.01	-0.01
Investing Cash Flow	-0.01	0.00	3.47	-3.59	-0.02	-0.01	-0.03
Dividends Paid	–	–	-0.31	-0.31	-0.03	-0.03	-0.03
Stock Issued	0.01	–	3.97	–	0.80	0.51	1.42
Debt Repaid	–	–	-0.08	-0.08	–	–	0.00
Financing Cash Flow	4.43	11	3.98	3.77	12	0.51	1.42
Foreign Exchange Rate Adjustments	0.04	-0.04	0.01	-0.09	0.02	–	–
Net Change in Cash	–	–	-0.90	-7.52	10	-0.20	0.81
Free Cash Flow	-7.68	-10	-8.38	-7.69	-1.56	-0.70	-0.59

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -2175.0%

Financial strength

Current ratio: 0.28
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 7.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –